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VIRUS-LIKE PARTICLES 
  
Traditional vaccines Subunit vaccines 
Peptide 
vaccines 
Live 
recombinant 
vaccines 
DNA 
vaccines 
Attenuated Inactivated 
Recombinant 
proteins 
Virus-like 
particles 
Safety Low Medium High Medium 
Price Cheap Medium Expensive Cheap Medium 
Administration Intramuscular 
Immunogenicity High Low High Low High Depends 
Adjuvant Yes Depends Yes No 
Design of recombinant 
baculovirus 
Infection of insect 
cells by 
recombinant 
baculoviruses Production of 
insect cells 
Systems biology 
Assembly of 
subunits into 
VLPs 
Clarification 
• Centrifugation 
• Membrane 
processes 
• Depth filters 
• Tangential flow 
microfiltration 
Intermediate purification 
• Tangential flow 
ultrafiltration/diafiltration 
• Adsorptive 
chromatography 
• Chromatography matrices 
based on pores 
membrane layers 
Polishing 
• Affinity 
chromatography 
• Ion-exchange 
chromatography 
• Size-exclusion 
chromatography 
• Tangential flow 
ultrafiltration/ 
diafiltration 
• Chemical inactivation 
treatments 
THE PRESENT: CERVARIX® 
• Recombinant vaccine against Human Papillomavirus 
• Bivalent: Against HPV types 16 and 18 
• Simple non-enveloped VLP composed by L1 protein 
• Use of aluminum hydroxide adjuvant 
CONCLUSIONS AND FUTURE PERSPECTIVES ABBREVIATIONS 
PRODUCTION PROCESS 
Monocistronic 
baculovirus 
Polycistronic 
baculovirus 
Co-infection 
Co-expression 
Upstream Production of 
baculoviruses 
Downstream 
High versatility 
High complexity 
Promoters power 
Disulfide bond formation 
Post-translational 
modifications 
Protein folding 
Glycosilation 
Proteolytic processing 
Contamination of 
baculovirus particles 
Advantages Disadvantages Solutions 
ADVANTAGES AND DISADVANTAGES 
Genetic modification of 
insect cells/baculoviruses 
Chaperones or foldases 
Proteolytic preservatives 
Diversity of downstream 
strategies 
The approval of Cervarix®  
meant the acceptance of BEVS 
technology and a boost to more 
VLP vaccines based on BEVS to 
reach the market 
BEVS is the most suitable and 
advantageous technology to 
produce VLP vaccines at large-
scale 
Systems biology and genetic 
engineering are expected to 
improve both vector technology 
and bioprocess engineering 
• Promoters choice: polh or p10 
• Other genetic modifications: 
deletion of cath and chiA 
VLP: Virus-Like Particle 
BEVS: Baculovirus-insect cell 
Expression Vector System 
HPV: Human Papillomavirus 
FDA: Food and Drug 
Administration 
• The second VLP-based approved vaccine 
• The first approved vaccine using BEVS 
• Produced by GlaxoSmithKline 
Biologicals 
• Approved by the FDA in 2009 
• Data from 13 clinical studies 
involving 30,000 females were 
submitted in support of licensure 
Information 
Achievements 
Simple VLP Complex VLP 
Definition 
Protein structures that mimic the organization of native viruses but 
lack the viral genome, becoming potential vaccine candidates 
• Number of structural proteins: Simple or complex 
• Presence of envelope: Enveloped or non-enveloped 
Types 
Vaccination role 
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